Cellectar Biosciences is entering a strategic partnership with City of Hope Cancer Center, one of the largest cancer research and treatment organizations in the United States, the organization announced recently….
NorthStar Medical Radioisotopes is signing a clinical supply agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials, the company recently…
SpayVac is partnering with BioVaxys Technology Corp. to field test single-injection, long-lasting immuno-contraceptive vaccines in farmed rainbow trout, the organization announced today. “We’ve been focused on developing vaccines to help…
Invenra is partnering with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients, the company announced today. According to a release, the…
Exact Sciences is collaborating with the Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients, the company announced recently. According to a release, the Mayo Clinic…
Usona Institute will begin its Phase 3 Clinical Trial investigating psilocybin for Major Depressive Disorder (MDD), the company announced today. According to a release, the uAspire trial will start with…
SHINE Technologies has signed a Memorandum of Understanding (MOU) with Orano to cooperate in the development of the U.S. pilot plant with commercial-scale technology for recycling used nuclear fuel from…
Exact Sciences has launched a hereditary cancer test in the United States called Riskguard, the company announced this week. According to a release, the test provides an individualized patient report…
Type One Energy announced today it is relocating to Clinton, Tenn., to build Infinity One, the company’s stellarator fusion prototype machine. According to a release, the project will be called…
Cellectar Biosciences enrolled its first patient in its Phase 1b clinical trial evaluating iopofosine I 131 in pediatric patients with relapsed or refractory malignant high-grade gliomas (pHGG), the company announced…
